FTC Forces Caremark to Unlock $13B in Patient Savings
The FTC has settled its insulin pricing case against Caremark, the CVS-owned pharmacy benefit manager, claiming up to $13 billion in patient savings over the next decade.
News
Two New Non-Invasive Tests Could Slash the Wait for an Endometriosis Diagnosis
Women in the UK wait more than nine years, on average, to be told they have endometriosis. A new pair of tests could start to close that gap and do it without surgery. On 7 July, the National Institute for Health and Care Excellence (NICE) published draft guidance recommending that two non-invasive diagnostic tests, Endotest … Read more
AlzeCure Pharma Secures a $2.2B QuantumCell Deal for Its NeuroRestore Platform
AlzeCure Pharma has found a partner for its Alzheimer’s program, and the numbers attached to the deal are eye-catching, though not all of them in the way the headline suggests. The Swedish biotech said on July 1 that it has signed an out-licensing and collaboration agreement with QuantumCell, a Danish “tech-enabled” biotech, handing over global … Read more
Boulevard Bio Secures Global Rights to a $1.6B Trispecific T-Cell Engager
Boulevard Bio is paying $20 million upfront and committing up to $1.6 billion in milestones for the global rights to MTS-128, a trispecific T-cell engager.
7 Market Access Trends Reshaping Pharma by 2027
The rules of pharmaceutical market access are being rewritten. From IRA-mandated price ceilings to AI-driven outcomes contracting.
Pfizer and Innovent Strike $10.5B Oncology Collaboration
Pfizer has signed one of the year’s largest cross-Pacific oncology deals, pledging $650 million upfront and up to $9.85 billion in milestones to co-develop 12 early-stage cancer assets with China’s Innovent Biologics.
The Biologics Patent Cliff: Inside Pharma’s 2026-2029 Reckoning
A four-year window will reshape biopharma: ten blockbuster biologics worth $136B in annual revenue face biosimilar competition between 2026 and 2029.
Lilly’s Quiet $21B Sprint: Seven Deals, One Strategy Hiding in Plain Sight
While the industry debated whether GLP-1 mania had peaked, Eli Lilly closed seven acquisitions in 134 days.
NHS Gives Green Light to Life-Changing SMA Treatments
NICE has recommended routine NHS access to nusinersen and risdiplam for spinal muscular atrophy.
EU Critical Medicines Act Fights Dangerous Supply Crisis
The EU’s Critical Medicines Act takes direct aim at the supply chain vulnerabilities that leave patients without essential drugs when it matters most.